@article{7c05f716b3194cf98e2b2355f3b495e0,
title = "Specific keynote: chemoprevention of ovarian cancer: the journey begins.",
author = "Ozols, {Robert F.} and Daly, {Mary B.} and Andres Klein-Szanto and Hamilton, {Thomas C.} and Bast, {Robert C.} and Brewer, {Molly A.}",
note = "Funding Information: The benefit of fenretinide in the chemoprevention of ovarian cancer was also suggested in a chemopreventive study in women with early-stage breast cancer. In a randomized clinical trial supported by the National Cancer Institute performed at the Istituto Nazionale Tumori, Milan, Italy, women with T1 or T2, N0, or M0 breast cancer were randomized to fenretinide (200 mg) daily for 5 years or to no treatment [64]. During the first years of intervention, six patients in the control group developed an ovarian carcinoma whereas no cases of ovarian carcinoma occurred during the same time period in the fen-",
year = "2003",
month = jan,
doi = "10.1006/gyno.2002.6686",
language = "English (US)",
volume = "88",
pages = "S59--66; discussion S67--6670",
journal = "Gynecologic oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1 Pt 2",
}